Emphasizing the tenet that antitrust laws are enacted to protect competition—and not competitors—the Third Circuit has rejected one competitor’s claim that Sanofi-Aventis had an unfair advantage in the anti-coagulant drug market.
In its 28-page opinion in Eisai v. Sanofi-Aventis, the U.S. Court of Appeals for the Third Circuit broke down each of plaintiff Eisai’s claims, rejecting them all as mischaracterizations of what was really happening in the market.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
